 BOSTON--BUSINESS WIRE--Verastem, Inc. Nasdaq:VSTM also known as Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced new data have been published today in The Lancet Oncology. The study evaluated the intermittent dosing schedule of VS-6766 formerly known as CH5126766 to inform further testing of VS-6766 as both a single agent in RASRAF-mutant cancers such as KRAS mutant non-small cell lung cancer NSCLC or in 